October 2019: On Wednesday, October 23, 2019, Bodor Laboratories, Inc. terminated its license agreement with Brickell Subsidiary, Inc., formerly known as Brickell Biotech, Inc. On that day, Bodor Laboratories, Inc. also filed suit against Brickell Biotech, Inc., in a case captioned, Bodor Laboratories, Inc. et al v. Brickell Subsidiary, Inc., Case No. 1:19-cv-24379-DLG (S.D. Fla).

October 2017: Bodor Laboratories’ licensee, Brickell Biotech, announces positive and statistically significant results in a confirmatory Phase 2b study of their licensed product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. [Link]

October 2017: Publication of a peer-reviewed article of potent analogues of our second generation soft corticosteroid. [Link]

March 2017: Publication of a peer-reviewed article identifying the esterase responsible for the metabolism of two soft corticosteroid drugs. [Link]

December 2015: Bodor Laboratories’ licensee Brickell Biotech obtains clinically meaningful Phase 2b study results with the novel topical soft-anticholinergic Sofpironium Bromide in patients with hyperhidrosis [Link]

October 2015: Bodor Laboratories organizes a symposium on “Retrometabolic Drug Design” at the 20th North American ISSX Conference in Orlando, FL [Link]

April 2015: Bodor Laboratories’ licensee Brickell Biotech executes an exclusive sublicense and development agreement for Sofpironium Bromide with Kaken Pharmaceutical Co., Ltd. In Japan [Link]

September 2014: Bodor Laboratories’ licensee Brickell Biotech obtains positive initial results from a Pilot Clinical Study of the novel topical soft-anticholinergic Sofpironium Bromide for the treatment of hyperhidrosis [Link]

May 2013: 9th Retrometabolism Based Drug Design and Targeting Conference in Orlando, FL

December 2012: Bodor Laboratories, Inc. enters into an exclusive license agreement for its novel topical soft-anticholinergic with Brickell Biotech, Inc. for the treatment of hyperhidrosis

October 2012: Publication of the book “Retrometabolic Drug Design and Targeting” by Wiley Publishing, authored by Dr. Nicholas Bodor and Dr. Peter Buchwald [Link]

December 2011: Bodor Laboratories, Inc. enters into an exclusive license agreement for its novel topical soft-steroid with Nephron Pharmaceuticals Corp. for ophthalmic use

October 2011: Bodor Laboratories, Inc. enters into an exclusive license agreement for its novel topical soft-steroid with Dechra Pharmaceuticals PLC for dermatological and otic use in animals

June 2011: 8th Retrometabolism Based Drug Design and Targeting Conference in Graz, Austria

November 2011: Bodor Laboratories moves into the office space at 4400 Biscayne Boulevard in Miami, FL

May 2009: 7th Retrometabolism Based Drug Design and Targeting Conference in Orlando, FL

May 2007: 6th Retrometabolism Based Drug Design and Targeting Conference in Göd, Hungary

January 2006: Bodor Laboratories is incorporated in the state of Florida